Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Wants Answers From Former Owner Of Its Branded Consumer Business

Executive Summary

Perrigo reported a $804m impairment for its European branded OTC drug and nutritional products business for the July-September period and will file an arbitration claim against its former owners. Company also highlights Rx-to-OTC switch opportunities.

You may also be interested in...



Perrigo Puts Tysabri On Block, Generic Topicals Under Microscope

A portfolio review concluded that 'the next step to unlock shareholder value is … exploring strategic alternatives for that Tysabri royalty stream,' CEO John Hendrickson said during Perrigo's third-quarter earnings briefing.

Differin Gel Enters Changed Marketplace Since Last OTC Acne Drug Approval

Galderma Labs' adapalene gel is pending launch as first OTC acne ingredient approved through an NDA and first new acne ingredient available OTC in 20 years, but company must play in a digitally-oriented marketplace.

Culture Shock In Europe For Perrigo With Branded Consumer Business

Less than a month after moving up from president to CEO, John Hendrickson tells analysts during the firm's first-quarter earnings briefing that Perrigo's private label OTC drug business remains strong, with the next launch ready to ship, but growing European branded consumer product sales is more of a long-term goal.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119494

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel